Eli Lilly and Co. has pulled the plug on a collaboration with a Massachusetts company to develop inhaled insulin for diabetics.
Alkermes Inc. said it received a letter Friday from Lilly terminating the development and license agreement for AIR Inhaled Insulin. The announcement was made shortly after Alkermes released a statement that Lilly was evaluating its business case for the drug.
AIR Insulin is being evaluated in a broad phase-3 clinical trial program with patients with type 1 and type 2 diabetes. Alkermes said it was not aware of any safety, efficacy or manufacturing issues that would lead to the termination of the agreement.
Copyright 2008 by United Press International
Related stories:
Study identifies new regulator of fat metabolism
Over the past several years, animal studies have shown that high-fat, low-carbohydrate “ketogenic” diets cause demonstrable changes in metabolism and subsequent weight loss. Now, researchers at Beth Israel Deaconess Medical Center (BIDMC) have identified a key mechanism behind this turn of events. Their findings, which appear in the June 2007 issue of Cell Metabolism, demonstrate that a liver hormone known as FGF21 is required to oxidize fatty acids – and thereby burn calories.
Molecular medicine comes to the rescue
On Monday, August 14, Lilly Jaffe, a six-year-old North Shore suburban girl who had been diagnosed with type 1 diabetes when she was one month old, checked into the Clinical Research Center at the University of Chicago Medical Center. On Friday, August 18, she checked out, starting to make her own insulin, well on her way to insulin independence and ready to get in a few days of beach time in Michigan before starting first grade.
Google polishes product line with Chrome browser
(AP) -- The new Web browser that Google Inc. released Tuesday is designed to expand its huge lead in the Internet search market and reduce Microsoft Corp.'s imprint on personal computers.
Hip Bone Density Helps Predict Breast Cancer Risk
Measuring a woman’s bone mineral density can provide additional information that may help more accurately determine a woman’s risk of developing breast cancer. That is the conclusion of a new study published in the September 1, 2008 issue of
Cancer, a peer-reviewed journal of the American Cancer Society. The study’s results suggest that incorporating bone mineral density tests with current risk assessments might significantly improve physicians’ ability to predict breast cancer risk in older, postmenopausal women.
Ancient Galactic Magnetic Fields Stronger than Expected
(PhysOrg.com) -- Mining the far reaches of the universe for clues about its past, a team of scientists including Philipp Kronberg of Los Alamos National Laboratory has proposed that magnetic fields of ancient galaxies like ours were just as strong as those existing today, prompting a rethinking of how our galaxy and others may have formed.
Brain stress system presents possible treatment
A brain circuit that underlies feelings of stress and anxiety shows promise as a new therapeutic target for alcoholism, according to new studies by researchers at the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health (NIH).
Blood testing for mood disorders
Indiana University School of Medicine researchers have isolated biomarkers in the blood that identify mood disorders, a breakthrough that may change the way bipolar illness is diagnosed and treated. The report will be published in the February 26 advance online edition of the journal
Molecular Psychiatry.
Risk said associated with Eli Lilly drug
A new experimental drug from Indianapolis-based Eli Lilly and Co. has been found to have a risk of major bleeding, sometimes even death, a report says.